CVM News and Press, Cel-Sci Corporation From 08/11/23

2023-08-11 08:47:18 ET Cel-Sci press release ( NYSE: CVM ): Q2 GAAP EPS of -$0.19. For further details see: Cel-Sci GAAP EPS of -$0.57

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2023, as well as key clinical and corporate developments. Clinical and Corporate Developments this quarter include: CEL-SCI had a productive pre-submission meeting with Canada&#x...

2023-07-25 11:16:57 ET Summary Cel-Sci is struggling to commercialize its Multikine cancer therapy; it recently closed on a small but expensive financing. The company has completed its initial end of phase 3 meeting with the FDA; it issued an inconclusive report. Cel-Sci is a ...

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the closing of its previously announced public offering of 2,500,000 shares of its common stock at a public offering price of $2.00 per share,...

2023-07-18 10:13:56 ET Gainers: iCAD ( ICAD ) +31% . Biophytis ( BPTS ) +27% . Hyperfine ( HYPR ) +15% . Cabaletta Bio ( VERU ) +12% . Mind Medicine (MindMed) ( MNMD ) +10% . Losers: Lixte Biotechnology ( LIXT ) ...

2023-07-18 05:30:30 ET Stock futures rose slightly as investors awaited U.S. retail sales data to shed light on the Federal Reserve's policy outlook. Here are some of Tuesday's biggest stock gainers and losers: Biggest stock gainers For further details see: Biggest stock mov...

2023-07-18 01:25:22 ET CEL-SCI ( NYSE: CVM ) has priced an underwritten public offering of 2.5 million shares of its common stock at a public offering price of $2.00/share, for gross proceeds of $5 million. The stock was down 18.9% at $2.32 after-hours on Mo...

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM) , a Phase 3 cancer immunotherapy company, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a public offering price of $2.00 per share, for...

2023-07-17 16:34:19 ET CEL-SCI ( NYSE: CVM ) plans to offer to sell shares of its common stock in an underwritten public offering, the company said Monday. Shares of the company -24% at $2.15 after hours. The underwriter has a 45-day option to purchase up to ...

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. The Company expects to grant the under...